TenQ · Equity ReportCharts view ⇢  Fact sheet  Updated 2026-09-04

Monster BeverageMNST

$42.9B market cap

Sells Monster energy drinks, distributed mostly by Coca-Cola bottlers.

$43.82-12.3% from 52-week high · delayed close as of 2026-09-04 · not investment advice
+40.3% vs S&P 500 (SPY) +20.3% over twelve months
$29.21$34.79$40.36$45.93$51.51Sep '25Nov '25Jan '26Apr '26Jun '26Sep '26
The verdict

Monster Beverage in 36 checks

Monster Beverage at a glance: how it scores on value, growth, quality, health, shareholder returns and trend. The fuller the shape, the stronger the company. Behind each axis are six pass-or-fail checks from its filings, spelled out in the chapters below. Point at an axis to see them.

VALUEGROWTHQUALITYHEALTHRETURNSTREND

A mixed picture - strengths and real weaknesses - 23 of 36 checks passed.

Advertisement
I

Value

●●●●●●3/6

What you pay today for what the business produces, measured against MNST's own history and its peers, never a universal rule.

Fairly priced on some measures, rich on others - earnings multiple above its own long-run norm.

20.3xown 11-year median 18x
4.7xown 11-year median 4x
4.9%cash earned per $ of price
-whole-business multiple
Today’s multiple

Is the price high or low right now, compared to what the market usually pays?

11-year median 18xP/E today 20.3x

At 20.3x earnings, the market is paying +14% more than MNST's own 11-year median of 17.8x. Expectations are elevated, so more has to go right to justify the price.

Valuation history

What has the market paid for MNST over the years?

0.0010.0020.0020152016201720182019202020212022202320242025202611-year median 17.8xP/E 20.28

2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages

At 20.3x earnings, the market is paying +14% more than MNST's own 11-year median of 17.8x. Expectations are elevated, so more has to go right to justify the price.

Free cash flow yield

What cash return does the business throw off per dollar of market value?

4.9%FCF yield today

0.0%2.5%5.0%20152016201720182019202020212022202320242025202611-year median 6.1%FCF yield 4.9%

2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages

At 4.9%, you get less cash per dollar of market value than the 11-year median of 6.1% - the market is charging more for the same cash.

What does “Value” actually mean?

Value asks what you pay for each dollar of earnings, sales or cash the business produces. A high multiple isn't automatically bad - fast growers earn theirs - but a price far above the company's own history means the market expects a lot to go right. We compare each multiple to the company's own past and to its sector, never to a universal rule.

How we scored it · 3 of 6 checks passed
Cheaper than its own history (earnings)no multiple history
Earnings yield beats a long bond (4%)4.9% vs 4.0%
Better cash yield than its own historyunder 3 years of cash-flow history
Free cash flow yield above 3%4.9% vs 3.0%
Cheap on enterprise valueEBITDA unavailable
Price isn't outrunning growthPEG 1.01
II

Growth

●●●●●5/6

What the company has actually reported - is it selling more, and is more of it becoming profit?

The business is genuinely growing - revenue +20.4% in the last year, and it's consistent.

+20.4%vs the year before
+9.5%compound annual
+35.2%net income growth
+20.1%compound annual
Revenue history

Revenue: is the business selling more than it used to?

0.00$5.0B2011201220132014201520162017201820192020202120222023202420252026$9.2B

◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year

Revenue reached $8.3B in 2025, compounding +10% a year since 2022 though the pace has cooled. The trailing twelve months are already running at $9.2B, ahead of the last full year.

Profit history

Net income: how much of that revenue becomes profit?

0.00$1.0B$2.0B2011201220132014201520162017201820192020202120222023202420252026$2.1B

◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year

Net income was $1.9B in 2025, compounding +17% a year over three years. Earnings per share moved +35% over the last twelve months. Trailing twelve-month profit stands at $2.1B.

Growth rate

How fast is it growing, year by year?

+11%revenue growth, FY 2025

0.0%25%2012201320142015201620172018201920202021202220232024202511%26%

In 2025 revenue grew +11% while earnings moved +26% - when the earnings line runs above revenue, each new dollar of sales is arriving more profitably.

Per-share growth

Revenue per share: is your slice growing as fast as the company?

$8.43revenue per share, FY 2025

0.005.0020112012201320142015201620172018201920202021202220232024202520269.362.13

2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year

Revenue per share reached $8.43 in 2025, compounding +12% a year against +10% for MNST as a whole. Buybacks added roughly 3.0 points to your per-share result. Free cash flow per share stands at $2.00.

What does “Growth” actually mean?

Growth here is what the company has actually reported to the SEC - not a forecast. We look at the last year, the three-year pace, whether growth is speeding up or slowing down, and whether it's been consistent rather than one lucky year. Hatched bars are fourth quarters we derived from annual filings (companies file a full-year 10-K rather than a Q4 report).

How we scored it · 5 of 6 checks passed
Outgrew its sector last year20.4% vs 3.6% (sector 70th pct, n=55)
Sustained growth beats its sector (3 years)9.5% vs 8.3% (sector 70th pct, n=52)
Profits grew last year35.2% vs 0.0%
Profit growth beats its peers20.1% vs 30.1% (sector 70th pct, n=40)
Growth is speeding up, not slowing1y 20.4% vs 3y 9.5%
Grew per share, not just in total42.4% vs 0.0%
III

Quality

●●●●●●6/6

Whether the growth makes real money - margins, returns on capital, and whether profits turn into cash.

Rare profitability: margins and returns on capital are well above its peers.

55.5%kept after direct costs
29.2%kept after running costs
22.7%profit on shareholders' money
27.8%against a 10% cost of capital
105%operating cash ÷ net income
Margins

Margins: of every $1 of sales, how much survives each cost layer?

0.0%25%50%201120122013201420152016201720182019202020212022202320242025202656%29%23%

2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year

Operating margin widened 4 points to 29% since 2022. After everything, 23 cents of each sales dollar reaches net profit.

Earnings quality

Earnings quality: do the reported profits turn into real cash?

0.00$1.0B$2.0B2011201220132014201520162017201820192020202120222023202420252026$2.2B$2.1B

2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year

Operating cash flow tracks reported profit almost exactly (105%). The earnings are real cash, not accounting.

Returns on capital

What does it earn on the money it uses?

0.0%50%201120122013201420152016201720182019202020212022202320242025202623%19%28%

2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year

ROE 23% and ROCE 28% sit close together - the returns come from the business itself, not from borrowing.

Income waterfall

Where does each dollar of revenue actually go?

$8.3BRevenue 2025$4.6BGross profit$2.4BOperating income$1.9BNet income

Of $8.3B in sales, $4.6B survives production costs, $2.4B survives running the company, and $1.9B - 23¢ of every dollar - reaches the bottom line.

Cash conversion

How much of every sales dollar ends up as free cash?

0.0%20%2011201220132014201520162017201829%2019202020212022202320242025202623%

◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year

24 cents of every sales dollar became free cash in 2025, up 13 points since 2022.

Spending intensity

What does staying competitive cost, per dollar of sales?

0.0%2.0%20112012201320142015201620172018201920202021202220232024202520261.5%1.5%

2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year

The biggest claim on each sales dollar is capital spending, at 2% of revenue (stock compensation 2%). That share has fallen since 2022, so the cost of competing is easing.

Operating leverage

When sales grow, do profits grow faster?

0.0%20%2012201320142015201620172018201920202021202220232024202511%25%

Operating profit outgrew revenue in only 2 of the last 5 years. Costs are growing roughly in step with the business, so scale isn't yet paying for itself.

Return on capital employed

Does MNST earn more on its capital than that capital costs?

0.0%50%20112012201320142015201620172018201920202021202220232024202510% cost-of-capital lineReturn on capital 28%

MNST earns 28.3% on the capital it employs, well above the 10% most investors treat as the cost of capital. It was 21.7% in 2022, so the trend is up, and the pace is picking up.

What does “Quality” actually mean?

Quality asks whether the growth makes real money. Margins show how much of each sale survives costs; return on equity shows what shareholders earn on their capital; and the profit-to-cash comparison catches companies whose accounting profits never turn into actual cash.

How we scored it · 6 of 6 checks passed
Better gross margins than peers55.5% vs 39.1% (sector 70th pct, n=52)
Runs leaner than peers (operating margin)29.2% vs 11.9% (sector 70th pct, n=53)
Actually profitableTTM net income $2.1B
Earns well on shareholders' money22.7% vs 17.0% (sector 70th pct, n=51)
Earns a real return on the capital it employs27.8% vs 10.0%
Profits are cash, not accounting1.05 vs 0.80
IV

Health

●●●●●●3/6

The balance sheet stress test: could MNST survive a bad year?

Financially sound overall, with one or two things worth watching.

-debt unreported
3.7xnear-term bills coverage
-earnings ÷ interest bill
$3.4Bcash plus short-term investments
Debt & cash

Could it handle its debt if things went wrong?

0.00$2.0B201220132014201520162017201820192020202120222023202420252026$199M$2.2B

2026 = the latest balance sheet (2026-06-30), not a fiscal year-end

Debt isn't clearly tagged in MNST's filings, so treat the balance sheet with extra care rather than assuming zero.

Shareholders' equity

Is the company's own capital growing or shrinking?

0.00$5.0B201220132014201520162017201820192020202120222023202420252026$9.4B

The company's own capital grew from $8.2B in 2023 to $9.4B (+14%). The business is building book value rather than consuming it.

What does “Health” actually mean?

Health asks one question: can the business survive a bad year? We check whether near-term bills are covered, whether debt is modest and shrinking, whether earnings comfortably pay the interest, and - for loss-makers - how many years of cash are left at the current burn rate.

How we scored it · 3 of 6 checks passed
Comfortable near-term liquidity3.73 vs 1.50
Debt isn't dominatingdebt unreported - cannot verify
Debt trending the right wayunder 5 years of balance-sheet history
Earnings cover the interestoperating income or interest expense unavailable
Converts sales to cash better than its sector24.3% vs 13.9% (sector 70th pct, n=56)
Self-fundingTTM free cash flow $2.1B
V

Shareholder returns

●●●●●●3/6

How much cash actually flows back to owners - dividends, buybacks, whether the share count truly falls, and whether what is handed back is affordable.

Cash comes back to owners, with a caveat or two in the checks below.

$221Mdividends plus buybacks
-last fiscal year
$104Mlast fiscal year
$126Mdilutes the buybacks
-12.1%since 2011 (as reported)
Capital returned vs stock comp

How much goes back to shareholders - and how much leaks out as stock compensation?

0.00$2.0B201120122013201420152016201720182019202020212022202320242025

Stock compensation ($126M) outweighs the $104M returned - the dilution is winning.

Dilution rate (split-adjusted)

How fast is your ownership being diluted - or concentrated?

0.0%10%201220132014201511%2016201720182019202020212022202320242025-2.8%

The count shrank 2.8% last year - buybacks are outrunning stock compensation.

Dilution against what it bought

MNST has issued or retired shares - did shareholders end up better off?

020040020112012201320142015201620172018201920202021202220232024202588554

Both lines start at 100 in 2011, so the gap between them is what each share gained or lost. Share counts are split-adjusted.

MNST has shrunk its share count -12% from 2011 to 2025, so each remaining share owns more of the business. Revenue per share is +454% over the same years.

Why compare buybacks with stock compensation?

A company can trumpet billions in buybacks while quietly issuing nearly as much stock to employees. What matters to you is the net effect: is the share count actually falling? If not, the 'return' is mostly recycling.

How we scored it · 3 of 6 checks passed
Share count isn't climbingshares down 7.7% over 3 years
Buybacks outpace the stock issued to staff$221M bought back vs $136M of stock compensation
What it hands back fits inside its cash flow10.5% vs 100.0%
Meaningful yield to owners (dividends and buybacks)$221M returned, 0.5% of market value
Buybacks are sustained, not one-off$221M bought back in the last twelve months, 0.00 the year before; no dividend
Buybacks growing$221M vs 0.00 the year before; no dividend
VI

Trend analysis

●●●●●●3/6

What the market is doing about all of the above. This is price behaviour, not a fact about the business - read it as the market's current opinion, scored on six checks like every other chapter. The market is the S&P 500, measured by the SPY ETF with dividends included, over 3 months (63 trading sessions) and 12 months (252).

Mixed signals from the market - some trends up, some rolling over.

+4.9%the long-term trend line
-2.1%S&P 500 (SPY): +4.7%
+38.1%S&P 500 (SPY): +20.0%
-12.3%drawdown from peak
Trend

How is MNST's trend actually behaving right now?

Price chart loads as you scroll…

Chart by TradingView

MNST is in a downtrend. The price is below the band where recent trading settled and that band is still falling, so nothing in the picture has turned yet. Both the last two weeks and the month-ago comparison point down as well, so nothing here disagrees with the downtrend. The band drawn for the coming weeks turns downward partway through, so that support is set to thin out from there.

How the trend above is worked out

The trend read comes from the daily Ichimoku picture, a standard trend indicator, translated out of its jargon. It builds a band from the midpoints of the last 9, 26 and 52 sessions' highs and lows - in effect, the range where recent trading has settled - and draws that band 26 sessions into the future. Price above the band is an uptrend, below it a downtrend, inside it no trend. Because the band is drawn forward, the support for the next few weeks is already fixed and a change of its direction can be seen coming. We also compare the last two weeks against the last month, and today's price against where it stood a month ago. None of this says anything about the business; it describes the price only, and it is not advice. Where a check says 'the S&P 500', the comparison is with the SPY ETF including dividends, on the same adjusted basis as the stock's own price: short means 3 months, 63 trading sessions; long means 12 months, 252.

How we scored it · 3 of 6 checks passed
Trading above its cloud0.00 vs 0.50
Long-term trend structure is healthy47.39 vs 41.78
Rising over 3 months-2.1% vs 0.0%
Beating the S&P 500 over 3 months-2.1% vs 4.7%
Beating the S&P 500 over 12 months38.1% vs 20.0%
Not in a deep hole-12.3% from its 52-week high
VII

Insider activity

informational

What the people running the company do with their own shares - reported to the SEC within two days, classified so pay-plumbing doesn't masquerade as conviction.

$0.00their own money
$16Moften pre-scheduled
6of the last filings
54grants · exercises · tax
Open-market flow

Are the people running it buying or selling with their own money?

$10M0.00Nov '25Dec '25Mar '26May '26Jun '26

No open-market buying, and $16M of selling across 5 months. Selling alone is a weak signal - much of it is pre-scheduled - but the absence of buying tells you no insider saw the price as a bargain.

The record

Who did what, exactly?

DateInsiderRoleTypeSharesValue
2026-06-10Guy CarlingCEO, EMEA and OSPSELL19,000$2M
2026-05-14Mark J HallDirectorexercise12,000$533,640
2026-05-14Mark J HallDirectorexercise15,000$549,300
2026-05-14Mark J HallDirectorexercise12,000$609,840
2026-05-14Mark J HallDirectorexercise15,000$904,500
2026-05-14Mark J HallDirectorSELL54,000$5M
2026-05-14Emelie TirreChief Strategy OfficerSELL10,000$857,400
2026-05-14Emelie TirreChief Strategy Officerexercise2,248$99,969
2026-05-13Thomas J KellyChief Financial OfficerSELL7,000$614,670
2026-05-13Emelie TirreChief Strategy Officerexercise17,752$789,431
Why do the transaction types matter so much?

Most insider filings are not trades: stock grants, option exercises and tax withholding are how executives get paid, and gifts are estate planning. The signal lives in open-market transactions - a buy means an insider chose to spend their own cash on the stock. Sells are murkier: many are pre-scheduled 10b5-1 plans set months in advance. That's why the chart counts only open-market activity, and the table labels every row.

§

Recent filings

  • 10-Q Quarterly report
  • 10-Q Quarterly report
  • DEF 14A Proxy statement
  • 10-K Annual report
  • 10-Q Quarterly report
  • 10-Q Quarterly report
  • 10-Q Quarterly report
  • DEF 14A Proxy statement
A short weekly note on what changed in the numbers, coming soon.One email a week: the charts that mattered, nothing else.